ReViral names Pharmasset founder as board member
This article was originally published in Scrip
Executive Summary
Cardiff, UK-based ReViral, an antiviral drug discovery and development company focused on diseases caused by the respiratory syncytial virus (RSV), has named Professor Raymond Schinazi to its board as a non-executive director – effective from 9 April 2014. Professor Schinazi is the founder of several biotechnology companies including Pharmasset (acquired by Gilead, January 2012), where he chaired the company's board during the discovery of hepatitis C drug Sovaldi (sofosbuvir).
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.